Tumor location is a key decision factor for 1st-line mCRC treatment (ID 1852)
Choosing the best 1st-line treatment for RAS wt mCRC patients (ID 1853)
Cetuximab rechallenge in 3rd line mCRC can provide a new standard of care (ID 1854)
Panel discussion: Asian hot topics (ID 1855)